Doctor of Osteopathy Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Adedeji Olusanya

Pain Medicine San Antonio, TX Doctor of Osteopathy

NPI 1649899097 CMS profile 11420228

5282 Medical Dr Ste 180, San Antonio, TX 78229

Open in the dashboard

General payments

$15,416

98 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Adedeji Olusanya of San Antonio, TX is reported in the CMS Open Payments database as having received $15,416 across 98 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,388 43
2024 General $11,691 48
2023 General $124 1
2022 General $212 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Adedeji Olusanya
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Adedeji Olusanya were reported at $3,388. Among 1,144 Pain Medicine profiles paid that year, the median was $402 and the middle half received between $130 and $1,173.

Show as a table
Year Adedeji Olusanya Pain Medicine median Middle half National median
2019 $0 $409 $115–$1,311 $163
2020 $0 $214 $66–$666 $114
2021 $0 $299 $84–$899 $132
2022 $212 $335 $103–$1,149 $149
2023 $124 $376 $114–$1,228 $160
2024 $11,691 $387 $115–$1,173 $164
2025 $3,388 $402 $130–$1,173 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Medtronic, Inc. $10,825 34 payments
  2. Boston Scientific Corporation $1,128 19 payments
  3. Globus Medical, Inc. $943 8 payments
  4. Nevro Corp. $771 10 payments
  5. Abbott Laboratories $563 5 payments
  6. Spinal Simplicity, LLC $245 4 payments
  7. Averitas Pharma Inc. $227 6 payments
  8. Nalu Medical, Inc. $170 2 payments
  9. AbbVie, Inc. $154 4 payments
  10. BIOTRONIK NRO, Inc. $147 1 payment
  11. Other $243 5 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Grant $8,000 1 payment
  2. Food and Beverage $6,183 88 payments
  3. Travel and Lodging $1,233 9 payments
Products named General payments · program years 2022–2025
  1. SYNCHROMEDII $8,445 6 payments
  2. INTELLIS ADAPTIVESTIM $2,189 24 payments
  3. Senza Spinal Cord Stimulator $589 4 payments
  4. Senza Spinal Cord Stimulator $527 8 payments
  5. Vyrsa V1 $493 5 payments
  6. PROCLAIM Structural Heart $302 3 payments
  7. General - Pain Management $273 3 payments
  8. WaveWriter Alpha Prime 16 $271 3 payments
  9. PROCLAIM Structural Heart $261 2 payments
  10. HA MINUTEMAN G3-R $245 4 payments
  11. Other $1,671 31 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

344

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$8,843

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

65.4%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 153 $5,111
Morphine Sulfate Generic 14 $890
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 32 $803
Pregabalin Generic 33 $542
Morphine Sulfate Er Morphine Sulfate Brand 24 $466
Acetaminophen-Codeine Acetaminophen With Codeine Brand 16 $264
Tramadol Hcl Generic 23 $213
Methadone Hcl Generic 16 $196
Baclofen Generic 11 $158
Gabapentin Generic 11 $105

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Qutenza
  • Averitas Pharma Inc. $166
$166 — —
QULIPTA
  • AbbVie, Inc. $50
$50 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

98 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record